Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 10400
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
REYON Pharmaceutical Co., Ltd. manufactures and sells finished medicines and APIs in South Korea and internationally. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Data is available to registered users only
Buy
Sell